Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China

New England Journal of Medicine

Volumn 364, Issue 7, 2011, Pages 638-647

  Liang, Xiao Feng ^a   Li, Li ^a   Liu, Da Wei ^a   Li, Ke Li ^a   Wu, Wen Di ^a   Zhu, Bao Ping ^b   Wang, Hua Qing ^a   Luo, Hui Ming ^a   Cao, Ling Sheng ^a   Zheng, Jing Shan ^a   Yin, Da Peng ^a   Cao, Lei ^a   Wu, Bing Bing ^a   Bao, Hong Hong ^a   Xu, Di Sha ^a   Yang, Wei Zhong ^a   Wang, Yu ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Chinese Field Epidemiology Training Program   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ADVERSE OUTCOME; ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHUS PHENOMENON; ARTICLE; BRAIN DISEASE; CHILD; CHINA; CONTROLLED STUDY; DRUG SAFETY; ERYTHEMA MULTIFORME; FACIAL NERVE PARALYSIS; FEBRILE CONVULSION; FEMALE; GUILLAIN BARRE SYNDROME; HEALTH PROGRAM; HEARING IMPAIRMENT; HUMAN; HYPERTENSION; INFLUENZA A (H1N1); LARYNX EDEMA; LYMPHADENITIS; LYMPHANGITIS; MAJOR CLINICAL STUDY; MALE; MENINGISM; NEURITIS; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; URTICARIA;

EID: 79951824264     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1008553     Document Type: Article

References (22)

1. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre double-blind, randomised, placebo-controlled trial. Lancet 2010;375:56-66.
2. State Food and Drug Administration of China. The license of pandemic H1N1 vaccine produced by Sinovac (Beijing) was approved by SFDA in September 2, 2009. (In Chinese.) (http://www.sda.gov.cn/WS01/CL0051/41151.html.)
3. Schonberger LB, Bregman DJ, Sullivan- Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23. (Pubitemid 10209694)
4. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barre syndrome following influenza vaccination. JAMA 2004;292:2478-81. (Pubitemid 39552672)
5. Ministry of Health of the People's Republic of China. Guideline for vaccination against pandemic (H1N1) influenza. Beijing: Ministry of Health, 2009.
6. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization (WPRO/EPI/99.01). Geneva: World Health Organization, 1999. (http://www.who.int/ immunization-safety/publications/aefi/en/AEFI-WPRO.pdf.)
7. Liu DW, Guo B, Cao LS, et al. Study on the surveillance of adverse events following immunization in China, 2005-2006. Chin J Vacc Immuniz 2007;13:505-13.
8. Wu WD, Liu DW, Wu BB, et al. Analysis on the surveillance of adverse events following immunization in China, 2007-2008. Chin J Vacc Immuniz 2009; 15:481-90.
9. Ministry of Health of the People's Republic of China. Guideline for the identification of adverse reaction after immunization. Beijing: Ministry of Health, 2008.
10. Idem. Chinese standard procedures for vaccination. Beijing: Ministry of Health, 2005.
11. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005;294:2720-5. (Pubitemid 41770101)
12. Vellozzia C, Brodera KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010;28:7248-55.
13. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424-35.
14. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405-13.
15. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361:2414-23.
16. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill Summ 2003;52:1-24.
17. Supplementary information on vaccine safety. Part 2. Background rates of adverse events following immunization: adverse events following influenza vaccine. Geneva: Word Health Organization, 2000. (http://www.who.int/vaccines- documents/DocsPDF00/www562.pdf.)
18. European Medicines Agency reaffirms efficacy and safety of H1N1 pandemic vaccines. (http://www.emea.europa.eu/pdfs/human/press/pr/74870709en.pdf.)
19. Safety of pandemic vaccines: pandemic (H1N1) 2009 briefing note 16. Geneva: World Health Organization, 2009. (http://www.who.int/csr/disease/ swineflu/notes/briefing-20091119/en/index.html.)
20. The preliminary report on adverse reaction following pandemic H1N1 vaccination and estimation of immunization data in Japan. (In Japanese.) (http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou04/pdf/091127-01a.pdf.)
21. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
22. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barre syndrome. Drug Saf 2009;32:309-23.